Phibro Animal Health Corp (PAHC) · Nov 4, 2026 · Earnings

Phibro earnings beat revenue estimates as Animal Health margins slipped

In line — Adjusted EPS $0.79 vs ~$0.78-$0.79 consensus

Phibro’s first-quarter earnings were broadly in line, with revenue ahead of estimates as Mineral Nutrition and Performance Products offset softer Animal Health results.

Phibro is in the early phase of integrating the Zoetis medicated-feed-additive portfolio while trying to shift growth toward Mineral Nutrition and Performance Products; its core Animal Health business is dealing with Brazil’s virginiamycin restrictions and a planned Chicago Heights plant closure. The quarter supports that transition, but it does not remove the execution issues.

Revenue was better than the market expected, but the earnings result itself was not a surprise. First-quarter sales reached $386.8 million, ahead of the roughly $382 million published consensus and up 6% year over year, while adjusted diluted EPS of $0.79 essentially matched the $0.78-$0.79 consensus range. The cleanest positive is therefore top-line execution, not a meaningful earnings beat.

Figure	Q1 2026	Q1 2025	Consensus
Net sales (Quarterly Results)	$386.8M (+6%)	$363.9M	~$382.4M
Adjusted diluted EPS (Adjusted Net Income)	$0.79 (+8%)	$0.73	~$0.78-$0.79
Adjusted EBITDA (Segment Results)	$64.3M (+4%)	$61.9M
Operating income (Consolidated Results)	$49.6M (-3%)	$51.3M
SG&A (Consolidated Results)	$78.9M (+15%)	$68.5M

The growth mix was encouraging, but it came from the smaller businesses rather than the core franchise. Mineral Nutrition sales rose 17% and Performance Products sales rose 16%, while their adjusted EBITDA increased 36% and 75%, respectively. That is evidence the acquired and adjacent businesses are contributing operating growth, not just revenue. The filing says, “Mineral Nutrition net sales of $73.6 million... increased $10.6 million, or 17%,” and “Performance Products net sales of $20.2 million... increased $2.7 million, or 16%.”

Animal Health remains the constraint. Sales grew only 3%, while segment adjusted EBITDA fell 1% as higher selling costs offset the benefit of higher gross profit. Within the segment, the $5.2 million decline in Brazilian virginiamycin sales was partly offset by stronger MFA demand, but nutritional specialties and vaccines both declined. The filing states, “Animal Health Adjusted EBITDA decreased $1.0million due to higher SG&A offsetting higher gross profit from increased sales.”

The reported net-income growth was helped by below-the-line items, while underlying cost pressure remains visible. GAAP net income rose 11%, but operating income fell 3% because SG&A grew 15%; lower interest expense, favorable foreign-currency movements and a lower tax rate more than offset that operating decline. Adjusted gross margin held at 34.0%, so the quarter did not show a clear improvement in underlying profitability. The filing says, “Operating income decreased $1.6million primarily due to higher SG&A partially offset by higher gross profit.”

Maintained guidance is reassuring but not new information. Fiscal 2027 sales, adjusted EBITDA and adjusted net-income ranges were unchanged from the August outlook, which already assumed no additional Brazilian virginiamycin sales. Any regulatory approval would still be upside, but the company has not converted that possibility into the base case. The filing explicitly says, “Our fiscal year 2027 financial guidance is as shown below, with our guidance maintained from the previous quarter.” 〔0〕

Bottom line: This was a modestly better-than-expected revenue quarter, powered by the newer growth businesses, but adjusted earnings merely met expectations and the core Animal Health segment weakened. The event modestly advances the transition story without changing it fundamentally.

What to watch next

November 5 earnings call; Brazil virginiamycin regulatory update

Original filing on SEC EDGAR

More Phibro Animal Health Corp news

Live · an AI on the whole US market

Breaking down Wall Street's information edge.

A buy-side analyst on every ticker.

It reads every public company's filing the second it drops — decoded into plain English, before it's a headline. The edge every investor deserves, not just the desks.

Trade the facts, not the FOMO.

Every event

8-Ks decoded the moment they file

Every number

Fundamentals, valuation, quality

What's next

Earnings calendar + the analyst view

scroll ↓

From filing to your screen in seconds

AllSight is the fastest.

DETECT

The moment it files

Every public company, around the clock. The AI never blinks and never takes lunch — nothing to set up.

filed 9:41:03 · decoded 9:41:19

DECODE

Plain English — never a call.

The event, the numbers, how it sits vs. expectations — in seconds. The AI decodes it; you pull the trigger.

DELIVER

On your screen, before the bell

Overnight and premarket, it's already read everything. You walk into every session with the setup — not scrambling to find it.

Understand it like a Wall Street analyst. Explained like a friend.

the raw filing — read the original on SEC.gov↗

decoded▸

AllSight · BlackBerry Q2 FY27

Revenue $163.3M vs ~$144M expected; adjusted basic EPS $0.07 vs ~$0.04 consensus — a real upside surprise.Income statement
QNX revenue +27% to $80.3M; segment EBITDA $29.0M from $20.5M. “Record performance… core automotive.”Segment — QNX
Licensing jumped to $22.1M from $6.6M — it amplified the beat, but it's less recurring than QNX, so the quality sits in QNX.Segment — Licensing
FY27 guide lifted to $616–636M rev / $141–158M EBITDA, above the prior $594–621M / $119–139M framework.Guidance
QNX growth, margins, cash and a raised outlook all beat. But licensing amplified it and Secure Comms is flat — net retention 91% from 93%.Segment — Secure Comms

Know a company all the way down.

Not just one filing. AllSight profiles every public company end to end — the numbers, the quality, the insiders, the smart money, the Street. One page, nothing missed.

Price & every insider trade, plotted
A quality score ranked against every peer
40+ valuation & profitability multiples
Where each one sits in its 5-year range
Whole-market insider flow, in real time
Which superinvestors are holding it
Analyst consensus & price target

Live · — filings read this week

AllSight gives you an edge others can't.

One scan before the open, one after the close — every filing on every ticker, already decoded. You walk into every session fully prepared.

Not investment advice · a neutral translation you can check against the original SEC filing

allsight.ai

Events/ANDE/8-K · Earnings

8-K · Item 2.02 · Earnings

The Andersons — a record Renewables quarter that beat profit expectations

Filed Aug 3, 2026ANDE · NASDAQ

AllSight readBeatPriced in▲ 1.8% since filed · reaction agrees

adj. EPS $2.15 vs ~$1.48 consensus

This filing tests whether The Andersons' sharp profit increase reflects broad operating improvement or a one-off renewable-fuels boost. It also separates strong adjusted earnings and cash generation from the quarter's legal and impairment charges.

The quarter was substantially stronger than both last year and the published earnings expectation. Adjusted EPS reached $2.15, versus $0.24 a year earlier and above the published consensus of about $1.48; reported EPS was $1.65. Adjusted EBITDA more than doubled to $140 million, while sales slipped modestly — the improvement came from margins and operating performance rather than higher revenue. Financial Highlights · Statements of Operations

Q2 ($M, exc. per-share)	Q2 2026	Q2 2025	YoY
Sales & merchandising revenue	3,097.7	3,135.9	−1%
Net income (attributable)	56.6	7.9	+48.7
Diluted EPS	1.65	0.23	+1.42
Adjusted EPS	2.15	0.24	+1.91
Adjusted EBITDA	140.3	65.2	+75.1
Agribusiness adj. pretax	20.3	16.8	+3.5
Renewables adj. pretax	88.4	9.6	+78.8
Cash from operations	487.9	299.3	+188.6
Cash from ops (pre-WC)	112.9	42.9	+70.1

Renewables drove nearly all of the upside — the operating backdrop was strong, but the result also benefited materially from tax credits. Renewables' adjusted pretax income rose to $88 million on record production, stronger ethanol margins and merchandising gains. It also received $24 million of 45Z producer tax credits, so this was not solely a repeatable plant-margin improvement; the company did cite healthy export and domestic ethanol demand as supportive. Renewables — Record Q2 · Segment Data

Agribusiness improved, but it was a supporting contributor rather than the main earnings engine. Adjusted pretax income increased to $20 million as fertilizer margins improved and merchandising benefited from commodity-price volatility, despite lower fertilizer volumes. Agribusiness — Improved Q2 · Segment Data

Cash generation improved and funding capacity is comfortable, while reported earnings still absorbed meaningful non-core costs. Operating cash flow was $488 million ($113 million before working-capital changes); capital spending was $76 million. Adjusted EPS excludes $0.50 of legal-settlement, impairment and transaction items, so the $2.15 adjusted result runs ahead of the $1.65 reported. Leverage stays below the <2.5× debt-to-EBITDA target; no new quantified full-year outlook was given. Cash & Liquidity · Adjusted Net Income

Community sentiment · 612 votes

58% bullish

Bull 58%Neu 27%Bear 15%

AllSight

AllSight Pro

A buy-side analyst on every ticker — reading the whole market the second it moves.

It reads every public company's filing the instant it drops and hands you what it means — in plain English, before it's a headline.

The read itself

Not another feed. A buy-side analyst that never sleeps, on everything.

Whole-market breadthevery public company

Not the 20 names CNBC repeats. Every ticker that files — thousands of companies, one AI reading all of them.

Filed-to-decoded in secondsspeed

Filed 9:41:03, decoded 9:41:19. You've got the catalyst while the tape is still moving and the crowd's still on the headline.

Past the headlinedepth

What actually happened, the numbers that matter, how it sits vs what the Street expected, and what it sets up next.

Source-grounded & neutralrigor

Every read traces to the words in the actual filing — click to see them. A translation you can check, never a buy/sell call.

Zero effort to youconvenience

Plain English, one glance. Follow your stocks and the moment any of them files, it's in your pocket — no watching, no digging.

All of it, livePro

Free reads every session once it closes. Pro reads it the moment it files: the whole market, all day, every day.

And then — go deeper

From "what happened" to "is it worth it."

Cheap or dear?Where it trades vs its own valuation history.

The quality score, in fullAll five dimensions, ranked against its sector.

Structure & multi-year trendsRevenue, margins, cash — the hard numbers, decoded.

Insider activityWho inside the company is buying and selling.

Analyst price targetsWhere Wall Street says every name is headed.

The whole company, one pagePrice, ownership, the full read — on any ticker.

Hire your personal buy-side analyst.

Trade one usual slippage for a whole market's rhythm.

Free

forever

Every closed session, on the whole market. The live session and the deep company read stay Pro.

Monthly

$29/mo

billed monthly

Everything, live — every session the moment it files, plus the full company read. Flexible, month to month.

Best value · save 40%

Annual

$17.40/mo

$209 billed yearly

about one slippage a month

Same full access — the whole market live and every company — at the lowest price. 40% off the monthly.

Billed today. Powered by Stripe · AllSight never sees your card.

Phibro earnings beat revenue estimates as Animal Health margins slipped

What to watch next

More Phibro Animal Health Corp news

Breaking down Wall Street's information edge.